Back to search

Peptide record

TPDB42844

RP7 SCR Anticancer standard
7 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42844
RP7 SCR
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 7-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation N-terminal: Acetylation
Sequence
Ac-RPPLVIC-NH2
Physicochemical Analysis
C36H64N10O8S1
ANDEQGHKMFSTWY
P
797.03
9.01
1
0
3
+1
0.67
1.043
152.86
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
0
0.00
1
Residue Composition
number
0
A
1
R
0
N
0
D
1
C
0
E
0
Q
0
G
0
H
1
I
1
L
0
K
0
M
0
F
2
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 1 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 1 K: 0 M: 0 F: 0 P: 2 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
7
C36H64N10O8S1
797.03
9.01
+1
0.67
1.043
Amidation
L
Linear
Acetylation
Anticancer
Migration and invasion enhancer 1 (MIEN1)
Evidence Records 4 records
Evidence 1 Activity

Activity

IC50
IC50 = 156 ± 8.15 µM
Anticancer
156

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2024

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 150 ± 10.32 µM
Anticancer
150

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2024
Evidence 3 Activity

Activity

IC50
IC50 = 128 ± 11.65 µM
Anticancer
128

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2024
Evidence 4 Activity

Activity

IC50
IC50 = 137 ± 5.98 µM
Anticancer
137

Target

Prostate Cancer
DU-145
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2024